BNTX BioNTech SE

$95.59

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

BioNTech SE's upcoming earnings report on November 3rd is set against a backdrop of stabilization, with the company's EPS estimate and whisper number both aligning at $0.00, suggesting a consensus around a breakeven performance. This aligns with the broader market sentiment that anticipates steady, if not spectacular, results. The revenue estimate of $841 million will be closely watched, as it reflects BioNTech's ongoing efforts to diversify beyond its COVID-19 vaccine success and into other therapeutic areas. With a market cap of approximately $25.95 billion, BioNTech remains a significant player in the biotech sector, and investors will be keen to see how the company leverages its robust financial position to fuel future growth. In the absence of recent news, the focus will likely be on strategic insights from management regarding pipeline developments and potential new partnerships, which could provide the necessary momentum for future earnings growth.

Updated On 11/21/2025

About BioNTech SE

BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.

Website: https://www.biontech.de

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1776985
Address
AN DER GOLDGRUBE 12, MAINZ, DE
Valuation
Market Cap
$23.74B
P/E Ratio
nan
PEG Ratio
0.04
Price to Book
1.08
Performance
EPS
$-3.13
Dividend Yield
—
Profit Margin
-24.20%
ROE
-3.36%
Technicals
50D MA
$104.15
200D MA
$105.23
52W High
$131.49
52W Low
$76.53
Fundamentals
Shares Outstanding
240M
Target Price
$141.79
Beta
1.08

BNTX EPS Estimates vs Actual

● Estimated
● Actual

BNTX News & Sentiment

Nov 19, 2025 • Benzinga NEUTRAL
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer - Elicio Therapeutics ( NASDAQ:ELTX )
BOSTON, Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Elicio Therapeutics, Inc. ( NASDAQ:ELTX, "Elicio" or the "Company" ) ) , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J.
Nov 17, 2025 • Zacks Commentary NEUTRAL
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
Nov 14, 2025 • Benzinga NEUTRAL
Deal Dispatch: WBD, Bill.com, C3 AI Auctions Shake Market - C3.ai ( NYSE:AI ) , BILL Holdings ( NYSE:BILL )
An auction is underway for Bill.com ( NYSE:BILL ) . The business-payments firm, according to Bloomberg, tapped a financial adviser to solicit bids. The sale follows activist pressure from Starboard Value, a firm known for buying up stakes in public companies to get deal processes going.
Nov 13, 2025 • Benzinga NEUTRAL
Why Is BioNTech Stock Falling Today? - Pfizer ( NYSE:PFE ) , BioNTech ( NASDAQ:BNTX )
Pfizer ( NYSE:PFE ) is reportedly offloading its remaining stake in Covid-19 vaccine partner BioNTech SE ( NASDAQ:BNTX ) . It seeks an overnight block trade of about 4.55 million American depositary receipts, priced between $108 and $111.70 apiece, according to a Bloomberg report.
Nov 13, 2025 • GlobeNewswire NEUTRAL
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
WARMINSTER, Pa., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ( Nasdaq: ABUS ) ( "Arbutus" or the "Company" ) , a clinical-stage biopharmaceutical company focused on infectious disease, today reported third quarter 2025 financial results and provided a corporate update.
Nov 12, 2025 • Benzinga SOMEWHAT-BULLISH
A Closer Look at BioNTech's Options Market Dynamics - BioNTech ( NASDAQ:BNTX )
High-rolling investors have positioned themselves bullish on BioNTech ( NASDAQ:BNTX ) , and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
Sentiment Snapshot

Average Sentiment Score:

0.101
50 articles with scored sentiment

Overall Sentiment:

Neutral

BNTX Reported Earnings

Aug 04, 2025
Jun 30, 2025 (Pre market)
-0.19 Surprise
  • Reported EPS: $-1.60
  • Estimate: $-1.41
  • Whisper: —
  • Surprise %: -13.5%
May 05, 2025
Mar 31, 2025 (Pre market)
0.53 Surprise
  • Reported EPS: $-1.82
  • Estimate: $-2.35
  • Whisper: —
  • Surprise %: 22.4%
Mar 10, 2025
Dec 31, 2024 (Pre market)
0.6 Surprise
  • Reported EPS: $1.08
  • Estimate: $0.48
  • Whisper: —
  • Surprise %: 126.6%
Nov 04, 2024
Sep 30, 2024 (Pre market)
2.58 Surprise
  • Reported EPS: $0.88
  • Estimate: $-1.70
  • Whisper: —
  • Surprise %: 151.8%
Aug 05, 2024
Jun 30, 2024 (Pre market)
-1.34 Surprise
  • Reported EPS: $-3.36
  • Estimate: $-2.02
  • Whisper: —
  • Surprise %: -66.3%
May 06, 2024
Mar 31, 2024 (Pre market)
-0.24 Surprise
  • Reported EPS: $-1.41
  • Estimate: $-1.17
  • Whisper: —
  • Surprise %: -20.5%
Mar 20, 2024
Dec 31, 2023 (Pre market)
-0.52 Surprise
  • Reported EPS: $1.90
  • Estimate: $2.42
  • Whisper: —
  • Surprise %: -21.5%
Nov 06, 2023
Sep 30, 2023 (Pre market)
0.77 Surprise
  • Reported EPS: $0.67
  • Estimate: $-0.10
  • Whisper: —
  • Surprise %: 770.0%
Aug 07, 2023
Jun 30, 2023 (Pre market)
0.17 Surprise
  • Reported EPS: $-0.79
  • Estimate: $-0.96
  • Whisper: —
  • Surprise %: 17.7%

Financials